227 withdrawn. 227 Phase 1, 89 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 227 | Withdrawn 227 |
| Phase 2 | 89 | Withdrawn 89 |
Follow Digestive System Diseases: new trials by email Literature Review of Digestive System Diseases trials Research Report on Digestive System Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC certepetide, nab-paclitaxel, gemcitabine - Pancreas Cancer, Pancreatic Carcinoma | Phase 1 / Phase 2 | Withdrawn | Lisata Therapeutics, Inc. | 2030-01-01 | 2025-06-06 | |
| Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function Larotinib - Esophageal Cancer, Advanced Solid Tumor | Phase 1 | Withdrawn | Sunshine Lake Pharma Co., Ltd. | 2026-10-30 | 2026-09-28 | |
| Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma Arm 1 cemiplimab, Arm 2 cemiplimab and fianlimab - Hepatocellular Carcinoma | Phase 1 | Withdrawn | Virginia Commonwealth University | 2026-10-01 | 2026-09-14 | |
| Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer Nogapendekin Alfa Inbakicept (N803), Sotevtamab, Zabadinostat (CXD101) - Pancreatic Cancer Resectable, Pancreatic Cancer | Phase 1 | Withdrawn | ImmunityBio, Inc. | 2026-09-01 | 2026-08-28 | |
| Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment NP-101 (3 g), NP-101 (4.8 g), NP-101 (6 g) - Hepatocellular Carcinoma | Phase 1 | Withdrawn | University of Florida | 2026-02-01 | 2026-02-18 | |
| Effect of Bitopertin on the Liver and on Levels of Protoporphyrin IX in Bile, Blood, Liver, and Stool in Patients With Erythropoietic Protoporphyria/X-linked Protoporphyria and Increased Liver Stiffness and/or Liver Enzymes at Baseline bitopertin - Protoporphyria | Phase 1 | Withdrawn | Wake Forest University Health Sciences | 2026-01-01 | 2026-01-29 | |
| STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma Aldesleukin, Biopsy, Biospecimen Collection - Locally Advanced Cervical Carcinoma, Locally Advanced Colorectal Carcinoma | Phase 1 | Withdrawn | City of Hope Medical Center | 2025-12-05 | 2025-12-24 | |
| BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma BC3402, Durvalumab, Tremelimumab - Hepato Cellular Carcinoma (HCC) | Phase 1 / Phase 2 | Withdrawn | Case Comprehensive Cancer Center | 2025-11-01 | 2026-02-19 | |
| FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma Biopsy, Biospecimen Collection, Computed Tomography - Advanced Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma | Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2025-10-01 | 2025-01-17 | |
| A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer Regorafenib, Lorigerlimab - Colorectal Cancer | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2025-09-03 | 2026-03-11 | |
| TCR1020-CD8 T Cells in KRAS-mutated Cancers TCR1020-CD8 T cells - Metastatic Pancreatic Adenocarcinoma, Colorectal Cancer | Phase 1 | Withdrawn | University of Pennsylvania | 2025-06-01 | 2025-06-25 | |
| S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC Combination (S095033 + paclitaxel) - Esophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | Withdrawn | Institut de Recherches Internationales Servier | 2025-05-01 | 2026-02-17 | |
| Phase I Clinical Study of Chondroitin Sulfate for Treatment of NEC Chondroitin sulfate - Necrotizing Enterocolitis, Intestinal Ischemia | Phase 1 | Withdrawn | Indiana University | 2025-01-01 | 2025-10-10 | |
| NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease Biological NTLA-3001 - Lung Disease, Pulmonary Disease | Phase 1 / Phase 2 | Withdrawn | Intellia Therapeutics | 2024-11-20 | 2025-01-17 | |
| Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 AB-201, Cyclophosphamide, Fludarabine - Breast Cancer, Gastric Cancer | Phase 1 | Withdrawn | GC Cell Corporation | 2024-10-31 | 2025-01-24 | |
| Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer Nivolumab, Entinostat, Montanide(R) ISA-51 VG Adjuvant - Neoplasms, Esophageal Neoplasms | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2024-08-02 | 2024-08-05 | |
| IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced by KRAS Mutations IX001 TCR-T cells - Pancreatic Cancer, Colorectal Cancer | Phase 1 | Withdrawn | Shanghai Pudong Hospital | 2024-07-01 | 2026-09-02 | |
| Dexamethasone/Pancreatic Clamp P&F Insulin human, Octreotide Acetate, Glucagon - Insulin Resistance, Prediabetic State | Phase 1 | Withdrawn | Columbia University | 2024-07-01 | 2024-07-10 | |
| Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers personalized vaccine, Nivolumab - Cancer of Gastrointestinal Tract | Phase 1 / Phase 2 | Withdrawn | University of California, San Diego | 2024-06-01 | 2024-06-10 | |
| Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC) INCB099280 - Hepatocellular Carcinoma | Phase 1 | Withdrawn | Abramson Cancer Center at Penn Medicine | 2024-05-01 | 2024-08-09 |
Showing 20 of 227. Sign in to see all of them.
Pancreatic Neoplasms (51) · Colorectal Neoplasms (34) · Carcinoma, Hepatocellular (28) · Stomach Neoplasms (21) · Colonic Neoplasms (15) · Liver Neoplasms (15) · Neoplasms (13) · Breast Neoplasms (12) · Esophageal Neoplasms (12) · Neoplasm Metastasis (12) · Rectal Neoplasms (11) · Crohn Disease (10) · Ovarian Neoplasms (9) · Liver Diseases (7) · Non-alcoholic Fatty Liver Disease (7)
Digestive System Neoplasms (145) · Neoplasms by Site (144) · Neoplasms (136) · Gastrointestinal Diseases (116) · Intestinal Diseases (82) · Gastrointestinal Neoplasms (74) · Liver Diseases (63) · Neoplasms by Histologic Type (59) · Pancreatic Diseases (59) · Endocrine System Diseases (58) · Endocrine Gland Neoplasms (57) · Colonic Diseases (54) · Intestinal Neoplasms (52) · Neoplasms, Glandular and Epithelial (51)
Gemcitabine (15) · Fluorouracil (12) · Oxaliplatin (9) · Leucovorin (8) · Taxes (8) · Bevacizumab (7) · Capecitabine (6) · Cisplatin (6) · Cyclophosphamide (6) · Irinotecan (6) · Sorafenib (6) · Cetuximab (5) · Nivolumab (5) · Radiosurgery (5) · Radiotherapy (5)
M.D. Anderson Cancer Center (11) · National Cancer Institute (NCI) (9) · Mayo Clinic (4) · Medical College of Wisconsin (4) · Roswell Park Cancer Institute (4) · Case Comprehensive Cancer Center (3) · Gilead Sciences (3) · Johns Hopkins University (3) · Stanford University (3) · University of Rochester (3) · Abramson Cancer Center at Penn Medicine (2) · Biolab Sanus Farmaceutica (2) · Boston Children's Hospital (2) · Bristol-Myers Squibb (2) · City of Hope Medical Center (2)
United States (93) · China (14) · Canada (6) · United Kingdom (5) · Australia (4) · France (4) · Germany (4) · Israel (4) · Belgium (3) · Spain (3) · Taiwan (3) · Brazil (2) · Denmark (2) · Egypt (2) · Italy (2)
Amy Lightner, MD (2) · Jennifer Eads, MD (2) · Jennifer Wu, MD (2) · Vincent Chung (2) · Wen Wee Ma (2) · Abdullah M Al-Osaimi, MD (1) · Adrian Miranda, MD (1) · Ahmed M Safar, MD (1) · Alan P. Venook, MD (1) · Ali Zarrinpar, MD (1) · Alka Goyal, MD (1)
PMID 15895401, PMID 18366995, PMID 18565579, PMID 18834631, PMID 18839053, PMID 19293782, PMID 19533014, PMID 21123824, PMID 22075702, PMID 22374640, PMID 23734882, PMID 23786302, PMID 24708667, PMID 26187510, PMID 26673692, PMID 27535748, PMID 33203645, PMID 37741968, PMID 39863139
2019 (4), P30CA016056 (2), UM1CA186644 (2), 2009 (1), 2016 (1), P01CA043904 (1), P30CA014089 (1), P30CA014599 (1), P30CA015083 (1), P30CA015704 (1), P30CA033572 (1), P30CA043703 (1), P30DK034989 (1), P30DK063608 (1), P50CA062924 (1)